NCT05282732Completed
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Acute Haemodialysis, Haemodynamically Instable Patients and Chronic Haemodialysis Patients
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
Retrospective analysis of performance and treatment data collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter \& Genius 90 Concentrates in acute haemodialysis, haemodynamically instable patients and chronic haemodialysis patients * to analyse performance and treatment data from patients treated with the investigational device * to evaluate the filter characteristics for aHD (Acute haemodialysis) patients * to evaluate the improvement of kidney function for aHD patients
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 119 (actual)
- First submitted
- 16 Feb 2022
- Start date
- 7 Oct 2022
- Primary completion date
- 15 Oct 2025
- Lead sponsor
- Fresenius Medical Care Deutschland GmbH
- Diseases
- Chronic kidney disease
- NCT number
- NCT05282732
What you commit to
- Study type: Observational
- Participants enrolled: 119
- From 7 Oct 2022 to the primary completion date, 15 Oct 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Simultaneous use of another filter/adsorber for another form of therapy
Who the study is looking for
- All patients with an indication for the extracorporeal blood treatment suffering from renal insufficiency who received all treatments, between January 2019 and December 2019, with the investigational devices have to be included in the study in chronological order.
- For aHD patients: availability of at least 3 of the 5 primary variables (daily urea, creatinine, potassium, ultrafiltration and effluent volume) for 50 % of the documented treatments.
- For cHD patients: availability of the ultrafiltration values for all treatments and at least one value for urea and creatinine per week
Age in the registry: 18 years to - · Sex: All
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BG Klinikum Unfallkrankenhaus Berlin gGmbH Coordinator of this site? Confirm its status | Berlin | Germany | Unknown status |
| Medizinische Hochschule Hannover Coordinator of this site? Confirm its status | Hanover | Germany | Unknown status |
| Universitätsklinikum Jena Coordinator of this site? Confirm its status | Jena | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.